VocalTec to Host Conference Call on Merger With YMAX/magicJack

NETANYA, Israel and WEST PALM BEACH, Fla., July 19, 2010 (GLOBE NEWSWIRE) –
(Nasdaq:CALL), the inventor of VOIP and the softphone, with the goal of becoming
the leading provider of global voice over many platforms, will host a conference
call on Monday, July 19, 2010, to discuss the merger of VocalTec and YMAX Corp.,
the creator of magicJack and other products and services. The merger was
announced last Friday, July 16, 2010, and Monday is the new company’s first day
of trading on the Nasdaq under the new symbol CALL. For additional information
on this announcement, we recommend that investors read the full press release on
the merger at

http://www.prnewswire.com/news-releases/vocaltec-and-ymaxmagicjack-announce-merg

r-98616139.html, the VocalTec press release describing the stock split at

http://www.prnewswire.com/news-releases/vocaltec-announces-1-for-5-reverse-stock

split-98616124.html, and the form 6-K filing with the Securities and Exchange
Commission at www.sec.gov.

Conference Call Details:

Date: Monday, July 19, 2010
Time: 11:00 a.m. Eastern Time
North America: (877) 375-9147
International: (253) 237-1148

http://investor.shareholder.

com/media/index.cfm?c=ABEA-4
X2RRR&e=2&mediakey=D3B57DC8C
Webcast: 3BC4507F3F4BFA2C5731786

About VocalTec Communications

VocalTec Communications Ltd., the inventor of VOIP including the softphone, and
YMAX Corp., the creator of magicJack and other products and services, have
successfully merged and will be traded on the Nasdaq under the symbol CALL. The
combined company has the use of over 30 patents, some dating to when VocalTec
invented VOIP, and has the goal of becoming the leading provider of global voice
over many platforms. The company has achieved sales of over 6,500,000 of the
easy-to-use, award-winning magicJack since its launch in 2008. It is the largest
reaching CLEC (Competitive Local Exchange Carrier) in the United States in terms
of area codes available and certification in number of states, and the network
has historically had uptime of over 99.99%.

CONTACT: VocalTec
Investor Relations
Andrew Albrecht
561-771-CALL
ir@vocaltec.com
Kari Hernandez
Media Relations
512-382-8988
vocaltec@ink-pr.com

Penn National Gaming to Report First Quarter Results and Host Conference Call and Webcast on April 22

WYOMISSING, Pa.–(Business Wire)–
Penn National Gaming, Inc. (Nasdaq: PENN) announced today that it will release
its 2010 first quarter financial results at 7:00 a.m. ET on Thursday, April 22,
2010 and will host a conference call and simultaneous webcast at 10:00 a.m. ET
on Thursday, April 22, 2010. Both the call and webcast are open to the general
public.

The conference call number is 212/231-2929; please call five minutes in advance
to ensure that you are connected prior to the presentation. Interested parties
may also access the live call on the Internet at www.pngaming.com; allow 15
minutes to register and download and install any necessary software. Questions
and answers will be reserved for call-in analysts and investors. Following its
completion, a replay of the call can be accessed until May 22, 2010 by dialing
800/633-8284 or 402/977-9140 (international callers). The access code for the
replay is 21466145. A replay of the call can also be accessed for thirty days on
the Internet at www.pngaming.com.

About Penn National Gaming

Penn National Gaming owns and operates gaming and racing facilities with a focus
on slot machine entertainment. The Company presently operates nineteen
facilities in fifteen jurisdictions, including Colorado, Florida, Illinois,
Indiana, Iowa, Louisiana, Maine, Mississippi, Missouri, New Jersey, New Mexico,
Ohio, Pennsylvania, West Virginia, and Ontario. In aggregate, Penn National`s
operated facilities feature over 26,300 gaming machines, approximately 400 table
games, over 2,000 hotel rooms and over 959,000 square feet of gaming floor
space.

In the second half of 2010, the Company plans to add table games to its
facilities in West Virginia and Pennsylvania and expects to open the first video
lottery terminal facility in the state of Maryland in Cecil County. Through a
joint venture, Penn National is developing a full casino at Kansas Speedway in
Kansas City, which is anticipated to open in early 2012, and is also developing
casinos in Toledo and Columbus, Ohio, with openings targeted for the second half
of 2012. The Company recently announced its planned acquisition of Beulah Park
in Ohio in a transaction expected to close in the second quarter of 2010.

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results may vary
materially from expectations. Although Penn National Gaming, Inc. and its
subsidiaries (collectively “Penn National”) believe that our expectations are
based on reasonable assumptions within the bounds of our knowledge of our
business and operations, there can be no assurance that actual results will not
differ materially from our expectations. Meaningful factors that could cause
Penn National`s actual results to differ from expectations include, but are not
limited to, risks related to the following: our ability to maintain regulatory
approvals for our existing businesses and to receive regulatory approvals for
our new businesses; the passage of state, federal or local legislation that
would expand, restrict, further tax, prevent or negatively impact operations
(such as a smoking ban at any of our facilities) in the jurisdictions in which
we do business or seek to do business; the activities of our competitors and the
emergence of new competitors; construction factors, including delays, unexpected
remediation costs, local opposition and increased cost of labor and materials;
the costs and risks involved in the pursuit of those development opportunities;
the availability and cost of financing; the effects of local and national
economic, credit, capital market, housing, energy conditions on the economy in
general and on the gaming and lodging industries in particular; and other
factors as discussed in Penn National`s Annual Report on Form 10-K for the year
ended December 31, 2009, subsequent Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K as filed with the SEC. Penn National does not intend to
update publicly any forward-looking statements except as required by law.

Penn National Gaming, Inc.
William J. Clifford, 610-373-2400
Chief Financial Officer
or
Jaffoni & Collins Incorporated
Joseph N. Jaffoni, Richard Land
212-835-8500
penn@jcir.com

Copyright Business Wire 2010

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year…

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full
Year 2009 Results

CHARLOTTE, N.C., March 3, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter
and full year results for the period ended December 31, 2009 after the market
closes on Wednesday, March 10, 2010. Chelsea management will host a conference
call and live webcast to discuss these financial results and provide an update
on each of its development programs that afternoon at 4:30 PM ET.

Interested investors may participate in the conference call by dialing
877-638-9567 (domestic) or 720-545-0009 (international). A replay will be
available for one week following the call by dialing 800-642-1687 for domestic
participants or 706-645-9291 for international participants and entering
passcode 60600587 when prompted. Participants may also access both the live and
archived webcast of the conference call on Chelsea’s web site at
www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active
synthetic precursor of norepinephrine initially being developed for the
treatment of neurogenic orthostatic hypotension. In addition to Droxidopa,
Chelsea is also developing a portfolio of metabolically inert oral antifolate
molecules engineered to have potent anti-inflammatory and anti-tumor activity to
treat a range of immunological disorders, including two clinical stage product
candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior
safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include reliance on collaborations and licenses, risks and
costs of drug development, regulatory approvals, intellectual property risks,
our reliance on our lead drug candidate CH-1504, our history of losses and need
to raise more money, competition, market acceptance for our products if any are
approved for marketing, reliance on key personnel including specifically Dr.
Pedder, management of rapid growth, and the need to acquire or develop
additional products.

CONTACT: Chelsea Therapeutics
Investors & Media:
Kathryn McNeil
718-788-2856
mcneil@chelseatherapeutics.com